ICICI Prudential Nifty Pharma Index Fund - Direct Plan - Growth vs Kotak Nifty SDL Apr 2027 Top 12 Equal Weight Index Fund-Direct Plan-Growth
Side-by-side comparison of NAV, returns, expense ratio and star rating.
TopFund Analysis
Kotak Nifty SDL Apr 2027 Top 12 Equal Weight Index Fund-Direct Plan-Growth appears stronger based on its higher star rating of 5 compared to the 2-star rating of ICICI Prudential Nifty Pharma Index Fund - Direct Plan - Growth, indicating better performance or management quality. However, while Kotak's expense ratio is lower at 0.2012%, it has significantly lower returns over the 1-year and 3-year periods compared to ICICI's 24.97% and 21.58%, respectively. Investors should weigh the tradeoff between higher potential returns with ICICI's fund against the lower costs and higher rating of Kotak's fund.
ICICI Prudential Nifty Pharma Index Fund - Direct Plan - Growth
ICICI Prudential Mutual Fund
★★★★★
Other · Index Funds
Kotak Nifty SDL Apr 2027 Top 12 Equal Weight Index Fund-Direct Plan-Growth
Kotak Mahindra Mutual Fund
★★★★★
Other · Index Funds
| Metric | ICICI Prudential Nifty... | Kotak Nifty SDL Apr 20... |
|---|---|---|
| NAV | ₹21.96 | ₹13.39 |
| Star Rating | ★★ | ★★★★★ |
| Expense Ratio | 0.51% | 0.2012% |
| AUM | ₹163 Cr | ₹6,136 Cr |
| 1M Return | +10.74% | +0.62% |
| 3M Return | +7.74% | +1.28% |
| 6M Return | +14.27% | +2.88% |
| 1Y Return | +24.97% | +5.84% |
| 3Y CAGR | +21.58% | +7.48% |
| Risk Level | — | — |
| Fund Manager | Nishit Patel | Abhishek Bisen |